Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
Daraxonrasib demonstrated meaningful antitumor activity and a manageable safety profile in KRAS-mutant PDAC, with a median progression-free survival of 8.8 months and an objective response rate of 36% at the 300 mg dose
According to Zhang et al
For thoughts of self-harm or suicide, seek emergency help immediately before contacting your provider
All medications require eligibility and a prescription
In the Standards of Medical Care in Diabetes2021, the ADA recommend that for people with indications of high risk or established CKD either a sodium-glucose co-transporter-2 inhibitor (SGLT2i) or a glucagon-like peptide-1 receptor agonist (GLP-1 RA) be considered as a treatment option, independently of metformin use [15]
US$ 21.56
US$ 29.72
US$ 24.38
US$ 23.64
US$ 27.76
